Heather S. Bonner

Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease

James C. Arseneau, Robert W. Sponzo, David L. Levin et al. · New England Journal of Medicine · 1972 · 353 citations

Lymphoid Neoplasia, Second Malignant Tumors, Tumoral Pathology +13

Cytochrome c2 and reaction center of Rhodospeudomonas spheroides Ga. membranes. Extinction coefficients, content, half-reduction potentials, kinetics and electric field alterations

P. Leslie Dutton, K.M. Petty, Heather S. Bonner et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics · 1975 · 242 citations

Half-reduction Potentials, Biochemistry, Bioelectrochemistry +6

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.

S. Benham Kahn, C B Begg, J. J. Mazza et al. · Journal of Clinical Oncology · 1984 · 145 citations

Elderly Patients, Pharmacotherapy, Full Dose Versus +17

Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial.

Bruce G. Raphael, J. W. Andersen, R Silber et al. · Journal of Clinical Oncology · 1991 · 130 citations

Hematological Malignancy, Lymphoid Neoplasia, Eligible Patients +14

Human pharmacokinetics of WR-2721

Andrew T. Turrisi, Donna Glover, Heather S. Bonner et al. · International Journal of Radiation Oncology*Biology*Physics · 1986 · 93 citations

Human Pharmacokinetics, Pharmacology, Clinical Pharmacology +3